Private equity major Blackstone is considering selling Anthos Therapeutics, the developer of a new generation of blood thinners launched four years ago with backing from Novartis, according to a report by Reuters.
The report cites people familiar with the matter as highlighting that while Anthos does not yet have any approved products or generate revenue, its anticoagulants are currently undergoing late-stage clinical trials, meaning the company could be worth several billion dollars, significantly more than the $250m Blackstone invested when it founded the business in 2019.
Anthos’ most advanced product is a monoclonal antibody called abelacimab intended for patients with atrial fibrillation who do not respond well to other anticoagulants because of heavy bleeding. According to Anthos, research studies have shown that over 37 million people worldwide are diagnosed with atrial fibrillation, a heart rhythm disorder that significantly increases the risk of stroke.
Blackstone is working with investment bankers to explore a sale of Anthos, according to Reuters’ sources, although a final decision has yet to be made and the company may not be sold.